New drugs and treatments could be tested and made available to patients in Singapore more quickly. For starters, selected lower-risk late-stage clinical trials could be approved in half the time it takes now. CNA speaks to Associate Professor Danny Soon, CEO of the Consortium for Clinical Research and Innovation Singapore, which coordinates national clinical research programmes in Singapore. He is also Executive Director of the Singapore Clinical Research Institute, the coordinating body for clinical trials.